共找到 20 条结果
Although automated external defibrillators (AEDs) improve outcomes in shockable rhythms, their use introduces interruptions in chest compressions. In single-rescuer scenarios, AED retrieval and application may further increase no-flow time. The effect of dispatcher instruction strategy on these interruptions remains unclear. This study aims to evaluate whether AED-optimized dispatcher-assisted CPR (DACPR) instructions reduce no-flow time compared with standard instructions in a simulated single-rescuer OHCA setting. This prospective, randomized, controlled, parallel-group simulation trial will include adult laypersons and healthcare professionals. Participants will be allocated in a 1:1 ratio to either standard or AED-optimized DACPR instruction groups. All scenarios will be conducted in a controlled simulation environment with standardized AED accessibility (≤1 min retrieval distance) to isolate the effect of dispatcher communication on CPR performance. The primary outcome will be total no-flow time. Secondary outcomes include chest compression fraction, time to first compression, time to first shock, peri-shock pauses, and CPR quality metrics. This study investigates dispatcher instruction as a modifiable determinant of CPR interruption during AED use in single-rescuer scenarios. Findings will provide mechanistic insight into how communication strategies influence CPR quality under controlled conditions and may inform refinement of DACPR protocols. The study protocol was approved by the Institutional Ethics Committee of the University of Pécs (PTE/87175-1/2025). Written informed consent will be obtained. Results will be disseminated via peer-reviewed publication and scientific conferences. ClinicalTrials.gov: NCT07520877, prospectively registered on 8 April 2026.
暂无摘要（点击查看详情）
暂无摘要（点击查看详情）
FLNA encodes filamin A, a cytoskeletal actin-binding protein with critical roles in neuronal migration, mechano-transduction, and organ morphogenesis. Pathogenic FLNA variants are classically associated with periventricular nodular heterotopia (PVNH), epilepsy, and multisystem manifestations, although interpretation of missense variants remains challenging because of marked variable expressivity and limited functional evidence. We describe a mother-daughter pair carrying the heterozygous FLNA missense variant c.5776 C > T (p.Pro1926Ser). Clinical, electroencephalographic, neuroradiological, cardiological, and genetic data were retrospectively reviewed. Variant interpretation was performed according to ACMG/AMP criteria and supported by in silico and structural analyses. The proband, a 13-year-old girl, presented with migraine with aura, epilepsy responsive to levetiracetam, normal brain MRI, and QT interval prolongation, with no pathogenic variants identified in established long-QT genes. Her mother, who carried the same variant, had focal epilepsy, migraine with aura, and subtle PVNH on brain MRI. Additional family history included a maternally related male cousin reportedly hemizygous for the same variant and affected by a severe congenital multisystem phenotype including valvular and extracerebral abnormalities, overall consistent with FLNA-related disease. The p.Pro1926Ser substitution was absent from population databases, involved a highly conserved residue within immunoglobulin-like repeat 17 of the rod-2 domain, and was predicted to be deleterious by most computational tools. These findings support a likely contributory role of FLNA p.Pro1926Ser in a variably expressive neurodevelopmental and multisystem disorder in which epilepsy represents the predominant neurological phenotype.
Cancer survivors face unique and persistent health-related quality of life (HRQoL) challenges. Existing HRQoL questionnaires for survivors lack content regarding chronic physical issues and have typically included limited cancer types and languages/cultures, affecting breadth of content and generalisability. We developed and validated the EORTC QLQ-SURV100, a questionnaire to assess HRQoL in disease-free survivors of diverse cancers. A conceptual framework of HRQoL in cancer survivors, developed in previous study phases and conceptualised as survivors' self-reported physical, mental and social functioning and well-being, formed the basis for questionnaire content. The QLQ-SURV100 was administered to 1480 participants across 46 centres in 21 countries (31% breast cancer, 23% colorectal, 22% prostate, 24% other cancers), who had completed primary treatment 1-10 years earlier and had no evidence of active disease. Structural validity of the 21 multi-item questionnaire scales was assessed via confirmatory factor analysis; test-retest reliability via intraclass correlation coefficients (ICCs); construct validity through known-group comparisons; and cross-cultural validity and sex invariance through differential item functioning (DIF). Item response theory (IRT) analyses evaluated item redundancy and performance. The QLQ-SURV100 showed strong structural validity (Comparative Fit Index = 0.951; Tucker-Lewis Index = 0.944; Root Mean Square Error of Approximation = 0.046), with most standardised factor loadings > 0.7. Test-retest ICCs exceeded 0.7 for 27 of 35 scales and 0.6 for 34 scales. Known-groups analyses supported most hypotheses, confirming sensitivity to treatment, comorbidity, age, sex, and education. DIF analysis indicated minor cross-cultural item bias, but no sex-related DIF. IRT analysis found no redundant items. The EORTC QLQ-SURV100 showed satisfactory structural validity, test-retest reliability and construct validity; limited item redundancy; and measurement invariance across the sex and language groups examined.
Uric acid is the end product of purine metabolism and plays a dichotomous role in the human body. On one hand, it exerts antioxidant and neuroprotective effects; on the other hand, chronic hyperuricemia has been strongly associated with diseases beyond gout, affecting the cardiovascular, renal, metabolic, autoimmune, and central nervous systems (CNS). Excess uric acid promotes oxidative stress, endothelial damage, neurodegeneration, inflammasome activation, and impairs energy metabolism. It exacerbates autoimmune diseases, such as Systemic Lupus Erythematosus (SLE) and antiphospholipid syndrome (APS), by increasing inflammatory and oxidative damage, leading to greater end-organ damage. The British Society for Rheumatology, European League Against Rheumatism, American College of Rheumatology, and National Institute for Health and Care Excellence (NICE) have all established a "treat-to-target" approach for hyperuricemia with serum urate levels below 6 mg/dL and below 5 mg/dL in severe cases. Allopurinol and Febuxostat, xanthine oxidase inhibitors, are used as first-line pharmacological therapies for the treatment of hyperuricemia, whereas uricosurics and Interleukin-1 (IL-1) inhibitors are preferred in cases of refractory hyperuricemia. Lifestyle modifications, such as the Dietary Approaches to Stop Hypertension (DASH) diet, weight reduction, and smoking cessation, are also recommended for the long-term management of the disease. Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors, selective urate transport inhibitors, and plant-derived anti-inflammatory compounds have emerged as new treatments with promising responses. This review synthesizes the current literature on the multifaceted role of uric acid and emphasizes its systemic implications in chronic diseases. It also outlines the already established management options and new innovative therapies for managing this disease. Understanding this dichotomous role is essential for adopting a precise management approach that balances the protective and pathological effects of uric acid.
The reasons and physiological triggers for blood transfusion in critically ill patients are not well characterized. Beyond hemoglobin levels, hemodynamic instability is frequently cited, but its role across clinical contexts remains unclear. (1) To determine whether reasons and triggers for RBC transfusion differ across intensive care unit (ICU) days with varying transfusion intensity. (2) To describe reasons for non-RBC transfusions across these intensity groups. This sub-study of the prospective International Point Prevalence Study of Intensive Care Unit Transfusion Practices (InPUT) classified ICU days by transfusion intensity: nonmajor (1 RBC unit), major (≥2 units), and massive (≥6 units in a single event, ≥10 per day, or Massive Transfusion Protocol activation). ICU days without transfusion for active bleeding were classified as no bleeding. Significant differences in the multivariate composition of reasons for RBC transfusion were observed across intensity groups on permutational analysis of variance (PERMANOVA). Hypotension was the most frequently cited physiological trigger in nonmajor (54%, n = 80/148) and major transfusions (68%, n = 196/288), but less frequent in massive transfusions (30%, n = 14/64). Tachycardia was the second most common trigger in nonmajor (37%, n = 80/148), major (40%, n = 116/288), and massive transfusions (22%, n = 19/64). RBC transfusions are administered for distinct, intensity-dependent combinations of reasons and triggers. Transfusion intensity and clinical context are therefore key factors in evaluating transfusion practices. Among bleeding critically ill patients, hypotension and tachycardia are the most frequently cited physiological triggers.
Maltreated children may have multiple contacts with services both before and after possible identification by social services. This study examines contact patterns and pathways through public services among maltreated children who are known to social services, providing evidence about potential gaps in support. This study is part of the European Commission Horizon Health 2024 SERENA project. We link children recorded in child protection (CP) and children looked after (CLA) registers in Wales, England (Growing up in England and ECHILD) and in Denmark with their routine administrative data on health (hospital admissions, emergency care, general practice), education, employment and justice. This enables comparison of public service utilisation between children known to social services and a propensity-matched cohort not known to social services, from two years before to two-ten years after social service involvement. Result Findings will be presented by each country to examine whether consistent service contact patterns can help to identify maltreated or high-risk children, along with the pattern of service usage after the initial social service contact. Preliminary findings from Wales indicate that children on the CP register, but not CLA, use emergency departments more than the matched general population. Furthermore, CLA are more likely to depend on benefits and experience unemployment in adulthood compared to matched children and those on the CP register. Mapping service usage among maltreated children can inform targeted interventions to mitigate adverse outcomes and support early identification to prevent further harm, with potential for cross-national learning.
Integral drug-device combinations (iDDCs) are governed in the European Union (EU) under the medicinal products framework, but the medical device part must meet relevant requirements of the medical device framework. This implies increased complexity as actors with different responsibilities, expertise and priorities are involved. Regulation (EU) 2017/745 on medical devices (MDR) [1] came into effect on 26 May 2021. At the time of the repealed Council Directive 93/42/EEC on medical devices (MDD) [2], the European Medicines Agency (EMA) and EU National Competent Authorities (NCAs) were overseeing the evaluation of the quality, safety, efficacy, benefit/risk of the medicinal product and the relevant Essential Requirements according to the MDD of the integral medical device used in combination. Article 117 of the MDR introduced a fundamental change: notified bodies became responsible for assessing compliance of the integral medical device with the relevant General Safety and Performance Requirements (GSPRs), as set out in MDR Annex I. These GSPRs represent a more stringent set of requirements in comparison with the Essential Requirements in the MDD. One of the objectives of Article 117 and the MDR was to strengthen regulatory oversight of the device component of the iDDC and increase confidence in the regulatory system. Given the interface of the medicinal product and medical device legislations, the regulatory process for initial authorisation and lifecycle management of iDDCs is challenging to operate for pharmaceutical industry, EMA, EU NCAs and notified bodies. In particular, the implementation of Article 117 raised challenges to all stakeholders involved. In order to support implementation for pharmaceutical industry and EU medicines NCAs, EMA published dedicated guidance and engaged in various conferences and stakeholder meetings. EMA also facilitated discussion of issues with different actors and enhance mutual understanding and sharing of experience. Here, we present EMA's perspective on Article 117 implementation challenges and opportunities to tackle them.
Recent changes in European sewage sludge disposal address organic contaminant concerns, but risk continental-scale resource depletion. As the first methodology of its kind, a prediction model for central European sewage sludge compositions is developed from 730 data points, enabling resource quantification coupled with geographic distribution assessment. Limited sewage sludge constituent knowledge stems from undisclosed treatments, variable influent properties, and data confidentiality. These limitations were addressed by a review comprising 1908 literature sources and supplementary datasets. Thirty physicochemical parameters were quantified, and 7 factors were developed to contextualize UWWTPs within surficial-geological, pedological, and technological frameworks for data analysis. Linear regression (LR), random forest (RF), and XGBoost (XGB) were compared using robustness-enhanced preprocessing (IQR + Huber; ∼80% data retained), with performance evaluated against a mean baseline and transferability assessed via leave-one-country-out (LOCO) validation. Models outperform baselines for selected trace elements (SnO2, CoO, CdO, Cu2O, PbO, Sb2O3), and Sulfur, while most organic and mineral constituents remain near baseline, indicating dominant process control. LOCO results demonstrate European-scale transferability for selected constituents (CoO, CdO, Cu2O, K2O, P2O5, ash content). Surface-data-driven models cannot resolve point sources; however, removing influential outliers improves model stability and the reliability of large-scale resource recovery estimates, particularly when combining linear and non-linear approaches. Despite limitations due to missing plant-specific process data, this framework provides a scalable proxy for regional assessments. Future improvements should integrate broader compositional datasets and detailed operational variables to better link geographic drivers with treatment processes and enable more reliable identification of material streams within European sewage sludges.
Incidental prostate cancer (PCa) patients are currently stratified to either cT1a vs. cT1b stage, depending on tumor volume (< 5% vs. > 5%) in the resected tissue. We tested for other models that could improve cancer-specific survival (CSS) predictions. Incidental (cT1a/cT1b) PCa patients were retrospectively identified within the Surveillance, Epidemiology, and End Results (SEER) database (2004-2015). Kaplan-Meier plots illustrated CSS at 5 years of follow-up. Combination of variables resulted in three distinct stratification models based on cT1a vs. cT1b and Gleason score sum (GS). Multivariable Cox regression models that predicted CSS were used for area under the curve (AUC) quantification after 20-fold cross validation. We identified a total of 5155 incidental PCa patients. CSS at 5 years was 98% for cT1a vs. 90% for cT1b (p < 0.0001). CSS at 5 years for combination of cT1a and GS 6 patients was 99% vs. 92% for patients with either cT1b or GS ≥ 7 (p < 0.0001). Finally, for patients with GS < 8, CSS at 5 years was 98% vs. 72% for patients with GS ≥ 8 (p < 0.0001). The multivariable adjusted AUC was 0.83 vs. 0.82 vs. 0.88, for each model, respectively. Of all tested stratification models, the consideration of GS stratified between < 8 and ≥ 8 resulted in the best survival discrimination, as well as highest accuracy after cross-validation. In consequence, the use of this model (GS < 8 vs. ≥ 8) appears better suited than the standard cT1a vs. cT1b substaging, when CSS represents the endpoint of interest.
This dataset presents information on the viability of cryopreserved Echinococcus multilocularis (the Nemuro strain, Alaskan lineage) stored in liquid nitrogen. Protoscoleces and cyst residues were obtained from cotton rats experimentally infected with parasite eggs in the laboratory. These materials were mixed with a sperm cryopreservation solution and frozen in liquid nitrogen for one month. The viability of the cryopreserved material was evaluated by intraperitoneal injection into cotton rats, follows by the observation of cyst and protoscolex development within the peritoneal cavity at four months post-infection. The experiment was conducted independently on three separate occasions using two E. multilocularis strains (Nemuro and European strains). In total, E. multilocularis cysts were detected in 18 of the 20 inoculated cotton rats. Furthermore, the development of protoscoleces was observed in the cysts that developed in all animals. The protoscoleces purified from the cysts formed within the peritoneal cavity of a cotton rat were administered orally to a beagle dog, and the presence of parasite eggs in the feces was monitored. Consequently, parasite eggs were detected in the feces between days 30-35 post-infection. This confirms that the protoscoleces obtained from cryopreserved material can serve as an infection source for the definitive host. The methods described in this study will allow for the simple maintenance of E. multilocularis strains with minimal animal use and reduced costs.
Preterm birth (PTB) remains a significant public health concern despite advances in obstetric and neonatal care. Risk screening methods have modest predictive power, primarily because they rely on clinical risk factors that are not present in most women who experience a PTB. Unlike a single disease entity, PTB is a heterogeneous syndrome caused by various genetic, clinical, and environmental factors, and therefore, cannot be predicted by a single marker or risk indicator. For this reason, current risk assessment methods must be shifted from purely clinical indicators to ones that can also capture the underlying biology of the process. This expert opinion piece discusses the current state of risk screening in Europe and the importance of using a 'syndromic' rather than a 'single disease' view of PTB to guide future risk screening. A validated maternal serum biomarker test, marketed in the United States under the tradename PreTRM®, is also discussed as a tool that could potentially help address key shortcomings of risk screening methods, and thereby aid efforts to mitigate PTB, neonatal morbidity and mortality, and their associated costs.
To examine intraoperative and postoperative practices (antibiotic and antithrombotic prophylaxis, ear packing, behavioural recommendations, follow-up strategies) in exclusive endoscopic ear surgery management, based on a global survey of experienced surgeons. The setting is an international survey distributed via personal mailing lists and the International Working Group on endoscopic ear surgery. Anonymous responses were collected through Google Forms and analyzed using descriptive statistics, logistic regression models, and Kruskal-Wallis tests with post-hoc analyses to explore associations between geographic origin, surgical practices, and postoperative protocols. The result is a cross-sectional descriptive study. We collected responses from 44 surgeons across 21 different countries. Significant variability in surgical management practices was observed, often diverging from the current literature. Geographic origin and surgeon experience showed a limited association with specific practices. Notably, North American surgeons reported longer follow-up durations and more consistent use of cefazolin, whereas European surgeons demonstrated greater variability in antibiotic regimens. The survey reveals wide variability in the intraoperative and postoperative management of exclusive endoscopic ear surgery, driven more by individual preferences than by scientific evidence. The absence of consistent patterns based on geography or expertise highlights the lack of standardized, evidence-based protocols.
Pleural solitary fibrous tumours (pSFTs) are mesenchymal neoplasms with usually indolent behaviour, although a subset shows aggressive features with recurrence and metastasis. Due to this unpredictability, the 2020 WHO classification defines pSFTs as tumours with intermediate malignant potential, highlighting the need for reliable prognostic tools. This study compared the prognostic performance of the standard and revised Demicco scores in surgically treated pSFT patients, focusing on survival and recurrence prediction. In this multicenter retrospective study, patients undergoing surgical resection for pSFTs between 1993 and 2023 at four European thoracic surgery centers were included. All cases underwent centralized pathological review and reclassification according to 2021 WHO criteria. Risk stratification was performed using the standard (4-DC) and revised (n4-DC) Demicco models. Overall survival and recurrence were analysed using Kaplan-Meier and competing-risk methods. Prognostic performance was assessed with multivariable Cox models, Harrell's C-index, and time-dependent AUC. A total of 112 patients were included. Minimally invasive surgery was performed in 80%, achieving R0 resection in 88%. Overall survival at 1, 3, 5, and 10 years was 98%, 87%, 83%, and 70%, respectively. Both models stratified survival effectively, with worse outcomes in intermediate- and high-risk groups. The 10-year cumulative incidence of recurrence was 23%, reaching 50% in high-risk patients and 0% in low-risk patients. The revised model showed superior discrimination for recurrence (C-index 0.813), while survival prediction was comparable. Five-year AUC for recurrence and survival was comparable between the two scores (0.867). Roughly 14% of the cases were rescored (upgraded or downgraded) in the n4-DC. Demicco scores reliably predict outcomes in surgically treated pSFTs. The revised model improves recurrence prediction without significant survival advantage.
Effective management of postoperative pain is vital for recovery following pacemaker (PM) implantation. This study evaluated a pain management protocol incorporating clinical pharmacist consultation to improve patient outcomes and healthcare utilization. In this randomized, unblinded controlled trial, 60 adults undergoing PM implantation were assigned to either standard care (control) or standard care plus a structured clinical pharmacist consultation (intervention). Pain intensity was measured daily (Days 0-10) using the Numeric Pain Rating Scale. Quality of Life (QoL) was assessed on Days 0, 1, 7, and 10 via European Quality of Life 5-Dimensions 5-Levels (EQ-5D-5L) version and European Quality of Life visual analogue scale (EQ-VAS) instruments. Patient satisfaction was measured on Day 10 using the Short Assessment of Patient Satisfaction (SAPS). Pain intensity and QoL scores improved significantly over time in both groups, with no statistically significant differences between groups. Medication adherence, physician contacts, and unresolved adverse effects were comparable between groups. In contrast, patient satisfaction scores were significantly higher in the intervention group, particularly regarding care, communication, and perceived respect. Clinical pharmacist consultation did not significantly alter postoperative pain intensity or QoL outcomes following PM implantation. However, it was associated with higher patient satisfaction, suggesting a meaningful contribution to the patient experience. Further studies with larger sample sizes and longer follow-up periods are warranted to clarify the impact of pharmacist involvement on clinical outcomes.
Engineered microorganisms for environmental release (EMERs) hold a considerable potential for bioremediation of sites polluted with urban and industrial emissions. The growing availability of EMERs with phenotypes that can help recovering polluted sites and degraded ecosystems could become a phenomenal tool to tackle some of the most pressing contamination problems at very different scales worldwide. Yet, while their delivery to diverse environmental targets could have an immense benefit, the regulatory roadmap for permitting release-in particular in the European Union-is controlled by strict policies which become actual deterrents for the development of the field. In this Perspective, we have mapped the current state of regulatory affairs and entertain ways of moving from the existing legislation on genetic engineering to an informed discussion about the future of this technology, highlighting several important aspects of the new generation of molecular tools for precision genetic engineering. Furthermore, we advocate advancing towards a fresh mindset in which EMERs are not perceived as artificial intrusions into the natural world, but as our main allies to combat much of the damage that we have inflicted to the planet.
ObjectivePrevious studies have suggested potential associations between cathepsins and cholelithiasis. This study aimed to investigate the potential causal relationships among cathepsins, inflammatory proteins, and cholelithiasis using Mendelian randomization (MR), and to explore whether inflammatory proteins mediate the association between cathepsins and cholelithiasis.MethodsWe conducted a two-sample MR study using genome-wide association study (GWAS) summary statistics for cathepsins, inflammatory proteins, and cholelithiasis. Genetic associations for cathepsins were obtained from the INTERVAL study of European-ancestry individuals. GWAS data for inflammatory proteins and cholelithiasis were obtained from publicly available datasets, including European-ancestry cholelithiasis datasets from FinnGen and GCST90044196. The inverse variance weighted method was used as the primary MR analysis, with complementary and sensitivity analyses performed to assess the robustness of the findings. Multivariable and mediation MR analyses were performed to evaluate whether inflammatory proteins mediated the pathway from cathepsins to cholelithiasis.ResultsAfter correction for multiple testing, genetically predicted cathepsin B was associated with an increased risk of cholelithiasis. Mediation analyses suggested that part of the effect of cathepsin B on cholelithiasis may be mediated by fibroblast growth factor 19 (FGF19) and interleukin-6 levels. In the reverse MR analysis, genetically predicted cholelithiasis showed potential associations with two cathepsins and twelve inflammatory proteins.ConclusionsThis MR study provides genetic evidence for a potential association between cathepsin B and increased cholelithiasis risk. FGF19 and interleukin-6 may serve as partial mediators in this association.
Leishmaniasis is a chronic parasitic disease caused by a protozoan of the order Kinetoplastida, transmitted through the bite of infected sandflies. Its mucosal form with sinonasal involvement is exceptional but clinically relevant, potentially causing granulomatous lesions, nasal obstruction, and epistaxis, mimicking inflammatory or malignant disease. In the Old World (Europe, Asia, Africa), it is usually associated with Leishmania infantum, whereas in the New World (America) L. braziliensis predominates, generally following a previous or concomitant cutaneous lesion. Early diagnosis and treatment are crucial due to the risk of local and systemic progression. The aim of this study is to highlight the diagnostic pitfalls and management considerations of mucosal leishmaniasis confined to the nasal septum in a European clinical setting by presenting a case series. Three cases diagnosed between 2018 and 2023 were retrospectively reviewed. All were male patients (aged 37, 43, and 76 years) with mucosal leishmaniasis involving exclusively the nasal septum, without previous or concomitant cutaneous lesions and no history of travel to endemic areas. Diagnosis was confirmed by lesion biopsy and Giemsa staining, demonstrating the presence of intracellular amastigotes. All patients received treatment with liposomal amphotericin B. All three patients achieved complete clinical resolution. Reversible adverse effects were documented: two cases of acute renal failure and one case of sinus bradycardia, successfully managed with temporary treatment suspension and intensive hydration. Patient number 2, immunosuppressed due to Crohn's disease, experienced recurrence several years later, initially treated with fluconazole and, due to persistent lesions, with a second course of liposomal amphotericin B. Isolated septal mucosal leishmaniasis is a rare and potentially underdiagnosed entity, particularly in the absence of cutaneous lesions, requiring a high index of clinical suspicion and histopathological confirmation. Liposomal amphotericin B is effective and safe under close monitoring. Immunosuppression may increase the risk of recurrence, justifying prolonged follow-up and multidisciplinary management.
Lithium remains a cornerstone of bipolar disorder treatment, yet it has a narrow-therapeutic index and depends on renal and volume status. Glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide/GLP-1 agonists are now widely coprescribed in this population. Six bibliographically distinct reports published since 2025 describe lithium elevation or toxicity after initiation, switching, or escalation, and in June 2026 the European Medicines Agency's Pharmacovigilance Risk Assessment Committee opened a signal of a drug interaction leading to increased lithium levels. We separate three levels of evidence: (a) an uncontrolled pharmacovigilance signal; (b) plausible mechanistic pathways; and (c) a speculative temporal model. The candidate mechanisms are more constrained than previously appreciated: delayed gastric emptying alters absorption rate without demonstrably altering total exposure; GLP-1-mediated natriuresis acts in the opposite direction and does not persist; reduced lithium clearance after weight loss is sustained but quantitatively insufficient. The temporal framing is speculative and may partly reflect ascertainment bias. The reports describe two separable phenomena: acute toxicity events, largely explicable by intake and volume effects, and a sustained upward shift in concentration per unit dose, which is not. We set out falsifiable predictions and monitoring considerations, adopting rather than claiming the schedule proposed elsewhere.